Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles
Source abstract
Abstract
Liposomes are becoming increasingly important as drug delivery systems, to target a drug to specific cells and tissues and thereby protecting the recipient from toxic effects of the contained drug. Liposome preparations have been described to activate complement. In this study, we have investigated complement activation triggered by neutral dimyristoyl-phosphocholine (DMPC) liposomes in human plasma and whole-blood systems. Incubation in plasma led to the generation of complement activation products (C3a and sC5b-9). Unexpectedly, investigations of surface-bound C3 revealed contact activated, conformationally changed C3 molecules on the liposomes. These changes were characterized by Western blotting with C3 monoclonal antibodies, and by incubating liposomes with purified native C3 and factors I and H. Quartz crystal microbalance analysis confirmed binding of C3 to planar DMPC surfaces. In addition, we demonstrated that DMPC liposomes bound to or were phagocytized by granulocytes in a complement-dependent manner, as evidenced by the use of complement inhibitors. In summary, we have shown that C3 is activated both by convertase-dependent cleavage, preferentially in the fluid phase, by mechanisms which are not well elucidated, and also by contact activation into C3(H2O) on the DMPC surface. In particular, this contact activation has implications for the therapeutic regulation of complement activation during liposome treatment.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Complement system in diseases · Lipid Membrane Structure and Behavior · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (55)
Show source-provided references
1. Biophysical aspects of using liposomes as delivery vehicles10.1023/A:1020178304031 ↗
2. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention10.1016/j.addr.2011.06.017 ↗
3. Membrane lipid composition and cellular function10.1016/S0022-2275(20)34276-0 ↗
4. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes10.4049/jimmunol.146.12.4234 ↗
5. Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes10.1089/hum.1998.9.3-315 ↗
6. Liposome triggering of innate immune response: a perspective on benefits and adverse reactions10.1080/08982100902792855 ↗
7. Liposome clearance10.1023/A:1020134521778 ↗
8. Generation of iC3 at the interface between blood and gas10.1111/j.1365-3083.1992.tb02837.x ↗
9. Structures of complement component C3 provide insights into the function and evolution of immunity10.1038/nature04005 ↗
10. Generation of three different fragments of bound C3 with purified factor I or serum10.1084/jem.158.2.334 ↗
11. Human anaphylatoxin (C3a) from the third component of complement10.1016/S0021-9258(19)40758-8 ↗
12. The covalent-binding reaction of complement component C310.1042/bj1930115 ↗
13. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C310.1111/j.1749-6632.1983.tb18116.x ↗
14. Relation of a putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement10.1084/jem.152.4.1102 ↗
15. The internal thioester and the covalent binding properties of the complement proteins C3 and C410.1002/pro.5560060201 ↗
16. Formation of the initial C3 convertase of the alternative complement pathway10.1084/jem.154.3.856 ↗
17. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells10.4049/jimmunol.158.11.5455 ↗
18. Isolation and biochemical characterization of the iC3b receptor of Candida albicans10.1128/iai.61.4.1395-1399.1993 ↗
19. Liposome-mediated triggering of complement cascade10.1080/08982100802309552 ↗
20. Biodistribution of liposomes and C3 fragments associated with liposomes evaluation of their relationship10.1016/S0378-5173(00)00511-1 ↗
21. Liposome-complement interactions in rat serum: implications for liposome survival studies10.1016/0005-2736(94)90231-3 ↗
22. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes10.4049/jimmunol.118.1.342 ↗
23. Liposome clearance from blood: different animal species have different mechanisms10.1016/0005-2736(95)00184-0 ↗
24. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes10.1023/A:1018965121222 ↗
25. Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces10.1074/jbc.M110.180760 ↗
26. Complement-mediated acute effects of liposome-encapsulated hemoglobin10.3109/10731199909117481 ↗
27. Complement activation-related pseudoallergy caused by amphiphilic drug carriers: the role of lipoproteins10.2174/156720105774370212 ↗
28. Role of complements C3 and C5 in the phagocytosis of liposomes by human neutrophils10.1023/A:1015830306839 ↗
29. Large scale isolation of functionally active components of the human complement system10.1016/S0021-9258(19)69557-8 ↗
30. Isolation of beta If-globulin from human serum and its characterization as the fifth component of complement10.1084/jem.122.2.277 ↗
31. Purification of C3b inactivator and demonstration of its two polypeptide chain structure
32. Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments10.1016/0161-5890(87)90023-X ↗
33. Hirudin versus heparin for use in whole blood in vitro biocompatibility models
34. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, Compstatin10.1021/jm0603419 ↗
35. A simplified assay for the detection of C3a in human plasma employing a monoclonal antibody raised against denatured C310.1016/0022-1759(88)90229-3 ↗
36. Structural and functional analysis of C3 using monoclonal antibodies
37. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a
38. Verwendung von Schwingquarzen zur Wägung dünner Schichten und zur Mikrowägung
39. Quartz-crystal microbalance setup for frequency and Q-factor measurements in gaseous and liquid environments10.1063/1.1145396 ↗
40. Quartz-crystal microbalance with dissipation monitoring of supported lipid bilayers on various substrates10.1038/nprot.2010.65 ↗
41. Compstatin: a complement inhibitor on its way to clinical application
42. Complement in immune and inflammatory disorders: therapeutic interventions10.4049/jimmunol.1203200 ↗
43. The role of immunoproteins in the survival of liposomes in the circulation10.1615/CritRevTherDrugCarrierSyst.v14.i2.10 ↗
44. Liposome opsonization10.1081/LPR-64971 ↗
45. The interaticion of liposomes with the complement system: in vitro and in vivo assays10.1016/S0076-6879(03)73010-9 ↗
46. Localization of sites through which C-reactive protein binds and activates complement to residues 14–26 and 76–92 of the human C1q A chain10.1084/jem.175.5.1373 ↗
47. Surface-associated serum proteins inhibit the uptake of phosphatidylserine and poly(ethylene glycol) liposomes by mouse macrophages10.1016/S0005-2736(01)00292-9 ↗
48. Protein adsorption to polyethylene glycol modified liposomes from fibrinogen solution and from plasma10.1016/S0005-2736(01)00330-3 ↗
49. Interactions between DMPC liposomes and the serum blood proteins HSA and IgG10.1021/jp804641e ↗
50. Studies of serum protein adsorption at phospholipid surfaces in relation to intravenous drug delivery10.1016/S0927-7757(99)00164-8 ↗
51. Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with α2-macroglobulin10.1042/bj1930129 ↗
52. Binding of C3 fragments on top of adsorbed plasma proteins during complement activation on a model biomaterial surface10.1016/j.biomaterials.2004.05.011 ↗
53. Complement component C3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 110.4049/jimmunol.0902810 ↗
54. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction10.1111/j.1365-2249.1993.tb05916.x ↗
55. Conformational epitopes of C3 reflecting its mode of binding to an artificial polymer surface10.1016/0161-5890(93)90050-L ↗